Nanjing Staidson Biopharmaceutical

Nanjing Staidson Biopharmaceutical is a key subsidiary and manufacturing hub of Staidson (Beijing) Biopharmaceuticals, a leading Chinese biotechnology company. The company focuses on the research, development, and commercialization of innovative biologics and small molecules, particularly in the fields of neurology, immunology, and infectious diseases. Its flagship marketed product is Enjingfu (Rat Nerve Growth Factor), which is widely used in China for the treatment of nerve damage. The company's clinical pipeline features advanced candidates such as STSA-1002, a monoclonal antibody targeting C5, and BDB-001, a C5a inhibitor licensed for the Chinese market. Nanjing Staidson operates large-scale GMP manufacturing facilities to support both domestic commercialization and global clinical development.